--- title: "Provectus Biopharmaceuticals (PVCT) news: reverse split" url: "https://aibio.space/companies/provectus-biopharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PVCT reverse split and convertible notes news: Provectus holders authorize reverse split of between 1-for-10 and 1-for-50. Provectus Biopharmaceuticals, Inc." --- PVCT Provectus Biopharmaceuticals, Inc. OTC · United States # Provectus Biopharmaceuticals (PVCT) news PVCT reverse split and convertible notes news Listings · 2026-06-22 ## [Provectus holders authorize reverse split of between 1-for-10 and 1-for-50](https://aibio.space/news/provectus-holders-authorize-reverse-split-between-1-10-1-50/) Provectus holders authorized a reverse split of between 1-for-10 and 1-for-50, with the ratio left to the board, and a matching cut in authorized shares. The company had $251,291 of cash at December 31, 2025, and its net loss widened to $5.4 million. ## Latest Provectus Biopharmaceuticals news 1. 2025-01-22 Debt Financing [Provectus Biopharmaceuticals approves plan to seek up to $10,000,000 in convertible notes](https://aibio.space/news/provectus-biopharmaceuticals-approves-plan-seek-up-10-000-000/) The unsecured notes carry 8% interest and convert into Series D-1 preferred stock at $2.8620 per share. The board also approved the closing of a 2024 financing under which the company had received $1,000,000 in notes. ## Provectus Biopharmaceuticals at a glance - **Ticker**: PVCT - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $1.2 million ### Related companies - [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON - [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) NASDAQ: COYA - [Cognition Therapeutics](https://aibio.space/companies/cognition-therapeutics/) NASDAQ: CGTX - [Kailera Therapeutics](https://aibio.space/companies/kailera-therapeutics/) NASDAQ: KLRA - [Calidi Biotherapeutics](https://aibio.space/companies/calidi-biotherapeutics/) AMEX: CLDI - [Summit Therapeutics](https://aibio.space/companies/summit-therapeutics/) NASDAQ: SMMT - [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) NASDAQ: ADPT - [Cabaletta Bio](https://aibio.space/companies/cabaletta-bio/) NASDAQ: CABA ### Also on OTC - [TFA Therapeutics](https://aibio.space/companies/tfa-therapeutics/) RAJAF - [MULTICELL TECHNOLOGIES INC](https://aibio.space/companies/multicell-technologies/) MCET - [Hongchang International Co.](https://aibio.space/companies/hongchang-international/) HCIL - [Revium Rx.](https://aibio.space/companies/revium-rx/) RVRC - [Alterola Biotech](https://aibio.space/companies/alterola-biotech/) ABTI - [MARIMED INC.](https://aibio.space/companies/marimed/) MRMD ## What Provectus Biopharmaceuticals does Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines based on pharmaceutical-grade rose bengal sodium (RBS), a halogenated xanthene small molecule. The company says it is the first to advance RBS into clinical trials for the treatment of disease. Its candidates use different amounts of RBS, delivered by different routes, for each disease area. Clinical programs include intratumoral PV-10 in oncology, with pre-operative penile squamous cell carcinoma and FOLRINOX-refractory pancreatic ductal adenocarcinoma metastatic to the liver as co-lead indications. Topical PH-10 in dermatology has undergone multiple mid-stage trials for psoriasis and atopic dermatitis. Topical PV-305 for eye disorders such as infectious keratitis has undergone non-clinical study at the University of Miami's Bascom Palmer Eye Institute. Proof-of-concept and discovery programs cover oncology, hematology, wound healing, vaccine adjuvants, infectious diseases and computer modeling of amyotrophic lateral sclerosis. | Product or program | What it is | Stage | |---|---|---| | PV-10 | Intratumoral rose bengal formulation for melanoma and liver cancers | early-stage clinical trials for co-lead indications | | PH-10 | Topical PV-10 formulation for psoriasis and atopic dermatitis | multiple mid-stage clinical trials | | PV-305 | Topical PV-10 formulation for eye disorders such as infectious keratitis | non-clinical combination study | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/form10-k.htm). ## Provectus Biopharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$1.9 million](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/) | [$2.1 million](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/) | | Net income (loss) | [-$5.4 million](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/) | [-$4.7 million](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/) | | Cash from operations | [-$3.3 million](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/) | [-$3.3 million](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/) | | Cash and equivalents | [$251,291](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/) | [$307,442](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Provectus Biopharmaceuticals Did Provectus Biopharmaceuticals do a reverse stock split? Our latest story on this, dated Jun 22, 2026: "Provectus holders authorize reverse split of between 1-for-10 and 1-for-50". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/provectus-holders-authorize-reverse-split-between-1-10-1-50/). Has Provectus Biopharmaceuticals sold convertible notes? Our latest story on this, dated Jan 22, 2025: "Provectus Biopharmaceuticals approves plan to seek up to $10,000,000 in convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/provectus-biopharmaceuticals-approves-plan-seek-up-10-000-000/). What is the ticker symbol of Provectus Biopharmaceuticals? Provectus Biopharmaceuticals, Inc. trades under the ticker PVCT on OTC. Where is Provectus Biopharmaceuticals listed? Provectus Biopharmaceuticals, Inc. is listed on OTC. What is the SEC CIK of Provectus Biopharmaceuticals? The SEC Central Index Key (CIK) for Provectus Biopharmaceuticals, Inc. is 315545. Its filings are on SEC EDGAR. How many shares does Provectus Biopharmaceuticals have outstanding? 420,279,879 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Provectus Biopharmaceuticals listed under? Our directory records Provectus Biopharmaceuticals, Inc. under United States. What does Provectus Biopharmaceuticals do? Our directory classifies Provectus Biopharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Provectus Biopharmaceuticals? The ISIN recorded for Provectus Biopharmaceuticals, Inc. is US74373P1084. Does aibio.space cover Provectus Biopharmaceuticals? aibio.space lists Provectus Biopharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Provectus Biopharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Provectus Biopharmaceuticals develop? Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines based on pharmaceutical-grade rose bengal sodium (RBS), a halogenated xanthene small molecule. The company says it is the first to advance RBS into clinical trials for the treatment of disease. What is PV-10 from Provectus Biopharmaceuticals? PV-10: Intratumoral rose bengal formulation for melanoma and liver cancers Stage: early-stage clinical trials for co-lead indications. What is PH-10 from Provectus Biopharmaceuticals? PH-10: Topical PV-10 formulation for psoriasis and atopic dermatitis Stage: multiple mid-stage clinical trials. Is Provectus Biopharmaceuticals profitable? Provectus Biopharmaceuticals, Inc. reported a net loss of $5.4 million for the fiscal year ended Dec 31, 2025, and used $3.3 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Provectus Biopharmaceuticals Members talk about Provectus Biopharmaceuticals (PVCT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Provectus Biopharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-06-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/315545/000149315226029512/form8-k.htm) 2. 2026-04-30 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/315545/000149315226019805/formdef14a.htm) 3. 2026-04-20 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/315545/000149315226018081/formpre14a.htm) 4. 2025-06-20 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/315545/000164117225015695/form8-k.htm) 5. 2025-05-01 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/315545/000164117225007928/formdef14a.htm) 6. 2025-04-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/315545/000164117225005432/formpre14a.htm) 7. 2025-04-16 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/315545/000164117225004995/form8-k.htm) 8. 2025-01-22 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/315545/000149315225003193/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:PVCT on TradingView](https://www.tradingview.com/symbols/OTC-PVCT/). ## SEC filings and registration - **SEC name**: Provectus Biopharmaceuticals, Inc. - **CIK**: 315545 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PVCT (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 800 S. GAY STREET, KNOXVILLE, TN, 37929 - **Phone**: (866) 594-5999 - **Shares outstanding**: 420,279,879 as of 2026-08-11 (10-Q filed 2026-08-13) - **Former names**: PROVECTUS PHARMACEUTICALS INC; PROVECTUS PHARMACEUTICAL INC; ZAMAGE DIGITAL IMAGING INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/315545/000149315226037671/form10-q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/315545/000149315226031379/form8-k.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/315545/000149315226029512/form8-k.htm) filed 2026-06-22 - [8-K](https://www.sec.gov/Archives/edgar/data/315545/000149315226029280/form8-k.htm) filed 2026-06-18 - [10-Q](https://www.sec.gov/Archives/edgar/data/315545/000149315226022950/form10-q.htm) filed 2026-05-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/315545/000149315226019805/formdef14a.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/315545/000149315226018160/form8-k.htm) filed 2026-04-21 - [10-K](https://www.sec.gov/Archives/edgar/data/315545/000149315226012726/form10-k.htm) filed 2026-03-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000315545), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Provectus Biopharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker PVCT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Provectus Biopharmaceuticals, Inc. - **Ticker**: PVCT - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US74373P1084 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-PVCT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/provectus-biopharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Provectus Biopharmaceuticals (PVCT) news: reverse split", 2026-10-31, https://aibio.space/companies/provectus-biopharmaceuticals/